TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03035474

Intervention type: OTHER
Group type: OTHER
Intervention: Digital Engagement
Description: Patient engagement to improve self-management/medication adherence

Intervention type: OTHER
Group type: OTHER
Intervention: Digital Engagement
Description: Patient engagement to improve self-management/medication adherence
Study: NCT05440903

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TEDTalk
Description: A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
Study: NCT02276443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive standard chemotherapy
Study: NCT03035474

Intervention type: OTHER
Group type: OTHER
Intervention: Direct Engagement
Description: Health system engagement to improve local QI programs

Intervention type: OTHER
Group type: OTHER
Intervention: Direct Engagement
Description: Health system engagement to improve local QI programs
Study: NCT02081859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embryoscope
Description: The embryoscope is a microscope that allows for continuous time-lapse monitoring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Criteria
Study: NCT03438721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant obesity prevention
Description: Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial coaching
Description: Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
Study: NCT03444480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate
Description: Initial dose plus supplemental doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate
Description: Initial dose plus supplemental doses
Study: NCT04160975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about safety and effectiveness of adult seasonal flu vaccination
Description: The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about safety and effectiveness of adult seasonal flu vaccination
Description: The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about safety and effectiveness of adult seasonal flu vaccination
Description: The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about safety and effectiveness of adult seasonal flu vaccination
Description: The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about safety and effectiveness of adult seasonal flu vaccination
Description: The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
Study: NCT02276443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive standard chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive standard immunotherapy
Study: NCT04160975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video about safety and effectiveness of adult seasonal flu vaccination
Description: The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
Study: NCT00766350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
Study: NCT02687867

Intervention type: DRUG
Intervention: Dabigatran (Pradaxa)
Description: As prescribed by treating physicians

Intervention type: DRUG
Intervention: Vitamin K antagonist
Description: As prescribed by treating physicians
Study: NCT03759808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
Study: NCT01150669

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Samples are analyzed in laboratory studies
Study: NCT01854346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills group training, KONTAKT
Description: KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
Study: NCT00420511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 100 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: metformin 1000 mg twice a day (bid) by mouth (po)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin 1000 mg twice a day (bid) by mouth (po)
Study: NCT01756274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® NEXT BGMS
Description: Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® PLUS BGMS
Description: Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® Next EZ BGMS
Description: Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
Study: NCT03765593

Intervention type: PROCEDURE
Intervention: Biopsy Salivary Gland
Description: A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
Study: NCT02276443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04370340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BabySlide
Description: Application of BabySlide during vacuum-assisted births for perineal protection
Study: NCT03765593

Intervention type: PROCEDURE
Intervention: Biopsy Salivary Gland
Description: A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.

Intervention type: PROCEDURE
Intervention: Biopsy Salivary Gland
Description: A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.

Intervention type: PROCEDURE
Intervention: Biopsy Salivary Gland
Description: A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
Study: NCT04171609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
Study: NCT01474590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epiduo/Tactuo
Description: topical to the face, once daily in the evening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vehicle gel
Description: topical to the face, once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline 200mg
Description: oral, 2 capsules once daily in the morning with aglass of water and with food
Study: NCT02276443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo baseline lymph node evaluation
Study: NCT01220544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical transplantation with donor NK cells
Description: Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain \> 8 x 10e6 CD34+ cells/kg and \< 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
Study: NCT02276443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo baseline lymph node evaluation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo baseline lymph node evaluation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo standard ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo standard ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo standard ultrasound
Study: NCT03129425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReNACE Psychoeducational Intervention
Description: 9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: General Educational Program
Description: 5 sessions in groups of 15-20 people
Study: NCT01533298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CombiflexOmega peri
Description: intravenously over 3 days infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SmofKabiven peripheral
Description: intravenously over 3 days infusion
Study: NCT02342054

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI-TRUS fusion guided Single Frac HDR
Study: NCT02993991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor that targets human HDAC isoforms. It is an orally bioavailable, second generation benzamide inhibitor of HDAC 1, 2, 3 and 11 with broad spectrum antitumor activity in vitro and in vivo.
Study: NCT01474590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
Study: NCT03529747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online self-help
Description: As detailed in experimental arm description.
Study: NCT01958957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgolides Meglumine Injection
Description: 25mg, intravenous drip, once a day. Number of Cycles: 14 days.
Study: NCT00456690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional recommendations
Description: Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
Study: NCT02993991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human PD-L1. It is selective for recombinant PD-L1 and blocks the binding of recombinant PD-L1 to the PD-1 and CD80 receptors.
Study: NCT04178733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269 - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269 - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269 - SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269 - IV
Description: Administered IV
Study: NCT00510653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 600 mg by mouth daily for 6 Weeks
Study: NCT03330392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AGP
Description: take two tablets per day (500 mg/day) for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take two tablets per day (500 mg/day) for 8 weeks
Study: NCT00254579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: 15 mg/kg Q12W dosing regimen
Study: NCT02174588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam + propofol
Description: Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol are used for sedation drug
Study: NCT01900912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLTS
Description: The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
Study: NCT00917293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxal 5'-Phosphate
Description: Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 pills, po bid.
Study: NCT02094768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reduced Fat Milk
Description: Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
Study: NCT01086436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix ™
Description: Oral, single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, single dose
Study: NCT02094768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar Sweetened Soda
Description: Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
Study: NCT03786627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined NMES and motor control
Description: This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Motor control and placebo NMES
Description: This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
Study: NCT00763009

Intervention type: DRUG
Group type: OTHER
Intervention: dipyridamole
Description: 0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
Study: NCT01777672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and oral hygiene recommendations
Study: NCT01612871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen, Letrozole , Anastrozole, Exemestane
Description: Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
Study: NCT01777672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and oral hygiene recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and oral hygiene recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and oral hygiene recommendations

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral TRPV1 agonist
Description: Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
Study: NCT03798119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
Study: NCT00495040

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Description: 87.5 CGE with 2.5 Gy/fraction for 35 treatments